Lawrence Steinman

Lawrence Steinman's AcademicInfluence.com Rankings

Lawrence Steinman

Philosophy

#2443

World Rank

#4177

Historical Rank

Logic

#589

World Rank

#1056

Historical Rank

philosophy Degrees

Lawrence Steinman

Biology

#2725

World Rank

#4293

Historical Rank

Immunology

#100

World Rank

#106

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Lawrence Steinman's Degrees

Doctorate Medicine Stanford University
PhD Immunology Stanford University

Why Is Lawrence Steinman Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Lawrence Steinman is an immunologist and neurologist professor of pediatrics at Stanford University. Since 2015, he has been a member of the National Academy of Sciences.

(See a Problem?)

Lawrence Steinman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis (2002) (1710)
The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. (2000) (1447)
Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin (1992) (1209)
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease (2002) (1121)
The T lymphocyte in experimental allergic encephalomyelitis. (1990) (1083)
Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). (1996) (1056)
Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. (2011) (988)
A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell–mediated tissue damage (2007) (988)
Polyarginine enters cells more efficiently than other polycationic homopolymers. (2000) (980)
Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention (1988) (965)
Multiple Sclerosis: A Coordinated Immunological Attack against Myelin in the Central Nervous System (1996) (946)
The Influence of the Proinflammatory Cytokine, Osteopontin, on Autoimmune Demyelinating Disease (2001) (805)
A molecular basis for MHC class II--associated autoimmunity. (1988) (678)
Autoantigen microarrays for multiplex characterization of autoantibody responses (2002) (671)
Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. (1992) (639)
Multiple sclerosis: a two-stage disease (2001) (630)
Statin therapy and autoimmune disease: from protein prenylation to immunomodulation (2006) (616)
T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis (2010) (547)
T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination (1985) (542)
Elaborate interactions between the immune and nervous systems (2004) (505)
Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets (2008) (500)
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial (2000) (499)
How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis (2006) (496)
T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis (1986) (470)
Protective and therapeutic role for αB-crystallin in autoimmune demyelination (2007) (459)
Thymic selection determines gammadelta T cell effector fate: antigen-naive cells make interleukin-17 and antigen-experienced cells make interferon gamma. (2008) (443)
Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation (1992) (439)
Type II monocytes modulate T cell–mediated central nervous system autoimmune disease (2007) (436)
Treatment of Autoimmune Neuroinflammation with a Synthetic Tryptophan Metabolite (2005) (415)
Selection for T-cell receptor Vβ–Dβ–Jβ gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis (1993) (410)
Limited heterogeneity of rearranged T-cell receptor Vα transcripts in brains of multiple sclerosis patients (1990) (407)
1,25-Dihydroxyvitamin D3 Ameliorates Th17 Autoimmunity via Transcriptional Modulation of Interleukin-17A (2011) (405)
Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy (1989) (403)
Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein (1996) (398)
Inhibitory role for GABA in autoimmune inflammation (2010) (379)
PPAR-δ senses and orchestrates clearance of apoptotic cells to promote tolerance (2009) (340)
Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. (1994) (336)
Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. (1985) (328)
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. (2013) (328)
Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells (2007) (322)
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein (2007) (321)
Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine (2002) (316)
Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. (1999) (315)
Lipid microarrays identify key mediators of autoimmune brain inflammation (2006) (308)
Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab (2005) (305)
Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. (1990) (303)
Design of effective immunotherapy for human autoimmunity (2005) (290)
Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. (2007) (289)
Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity (2009) (284)
Erratum: A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell–mediated tissue damage (2007) (281)
Local Delivery of Interleukin 4 by Retrovirus-Transduced T Lymphocytes Ameliorates Experimental Autoimmune Encephalomyelitis (1997) (279)
Science Communication to the General Public: Why We Need to Teach Undergraduate and Graduate Students this Skill as Part of Their Formal Scientific Training. (2013) (275)
Assessment of Animal Models for MS and Demyelinating Disease in the Design of Rational Therapy (1999) (271)
CD4+ T-cell subsets in autoimmunity. (1997) (270)
Gene microarray identification of redox and mitochondrial elements that control resistance or sensitivity to apoptosis. (2000) (262)
Immunology of relapse and remission in multiple sclerosis. (2014) (259)
Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen (1993) (258)
Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. (2002) (255)
Suppressive vaccination with DNA encoding a variable region gene of the T–cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity (1996) (253)
Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. (2005) (251)
Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. (1999) (245)
A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. (1996) (241)
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis (2003) (240)
B-Lymphocyte-Mediated Delayed Cognitive Impairment following Stroke (2015) (240)
Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. (2006) (230)
Extensive fusion of haematopoietic cells with Purkinje neurons in response to chronic inflammation (2008) (228)
Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2 (2016) (226)
In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis. (1981) (224)
Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2 (2015) (223)
Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production (1994) (220)
A newly characterized HLA DQ beta allele associated with pemphigus vulgaris. (1988) (213)
Common variants in P2RY11 are associated with narcolepsy (2010) (213)
Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin (2006) (211)
T cell recognition as the target for immune intervention in autoimmune disease (1989) (209)
Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models (2018) (205)
Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. (2001) (199)
An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide (2001) (199)
A molecular trio in relapse and remission in multiple sclerosis (2009) (197)
Angiotensin II sustains brain inflammation in mice via TGF-beta. (2010) (196)
Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. (2007) (195)
HLA class II allelic variation and susceptibility to pemphigus vulgaris. (1988) (195)
A rush to judgment on Th17 (2008) (193)
Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes. (1997) (193)
Myoblast implantation in Duchenne muscular dystrophy: The San Francisco study (1997) (192)
Impaired neurosteroid synthesis in multiple sclerosis. (2011) (192)
Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM (2022) (190)
HDL-bound sphingosine 1-phosphate restrains lymphopoiesis and neuroinflammation (2015) (184)
Predominant expression of T cell receptor V alpha 7 in tumor-infiltrating lymphocytes of uveal melanoma. (1990) (178)
Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis (2008) (170)
Inhibition of nitric oxide synthase for treatment of experimental autoimmune encephalomyelitis. (1997) (168)
Involvement of distinct murine T-cell receptors in the autoimmune encephalitogenic response to nested epitopes of myelin basic protein. (1988) (166)
A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis. (1991) (166)
Predominant expression of a T cell receptor V beta gene subfamily in autoimmune encephalomyelitis [published erratum appears in J Exp Med 1988 Jul 1;168(1):455] (1988) (165)
In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor. (1983) (163)
Peroxisome proliferator–activated receptor (PPAR)α expression in T cells mediates gender differences in development of T cell–mediated autoimmunity (2007) (162)
Diverse Targets for Intervention during Inflammatory and Neurodegenerative Phases of Multiple Sclerosis (2003) (162)
Peroxisome proliferator-activated receptor (PPAR)α and -γ regulate IFNγ and IL-17A production by human T cells in a sex-specific way (2012) (159)
Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. (2007) (158)
Neuropeptides, via specific receptors, regulate T cell adhesion to fibronectin. (1998) (153)
Statins as potential therapeutic agents in neuroinflammatory disorders. (2003) (152)
Anti I-A antibody suppresses active encephalomyelitis: treatment model for diseases linked to IR genes (1983) (150)
ICAM-1 expression in autoimmune encephalitis visualized using magnetic resonance imaging (2000) (148)
Encephalitogenic T cell clones specific for myelin basic protein. An unusual bias in antigen recognition (1985) (147)
Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. (2001) (143)
Defective sphingosine-1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation (2013) (142)
T-cell receptor V alpha and C alpha alleles associated with multiple and myasthenia gravis. (1989) (140)
Administration of Neutralizing Antibodies to Interleukin-6 (IL-6) Reduces Experimental Autoimmune Encephalomyelitis and Is Associated with Elevated Levels of IL-6 Bioactivity in Central Nervous System and Circulation (1995) (140)
Inhibition of insulitis and prevention of diabetes in nonobese diabetic mice by blocking L-selectin and very late antigen 4 adhesion receptors. (1993) (139)
Involvement of both 'allergic' and 'autoimmune' mechanisms in EAE, MS and other autoimmune diseases. (2003) (137)
Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies (2019) (136)
Epitope spreading to citrullinated antigens in mouse models of autoimmune arthritis and demyelination (2008) (135)
The uptake of ( - 3 H) aminobutyric acid in the goldfish retina. (1971) (135)
Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice (2012) (134)
T cell receptors in murine autoimmune diseases. (1989) (134)
Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination (2003) (134)
Expansion of oligodendrocyte progenitor cells following SIRT1 inactivation in the adult brain (2013) (131)
Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins. (1989) (131)
Transcriptional analysis of targets in multiple sclerosis (2003) (129)
Differential Regulation of Chemokines by IL-17 in Colonic Epithelial Cells1 (2008) (128)
Analysis of T cell receptor repertoire of muscle-infiltrating T lymphocytes in polymyositis. Restricted V alpha/beta rearrangements may indicate antigen-driven selection. (1993) (128)
Immune Therapy for Autoimmune Diseases (2004) (126)
Nuanced roles of cytokines in three major human brain disorders. (2008) (126)
In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. (1988) (126)
Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms (1997) (125)
Mixed results with modulation of TH-17 cells in human autoimmune diseases (2010) (125)
Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. (2014) (122)
Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system (2009) (121)
Leber's disease and dystonia (1986) (121)
Myelin-Specific Cd8 T Cells in the Pathogenesis of Experimental Allergic Encephalitis and Multiple Sclerosis (2001) (121)
Glia-dependent TGF-beta signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis. (2007) (121)
HLA-DQ BETA-CHAIN POLYMORPHISM LINKED TO MYASTHENIA GRAVIS (1986) (120)
Natalizumab: bench to bedside and beyond. (2013) (118)
Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B-cell epitope and a model of its features. (1995) (117)
Response to Comment on "The Influence of the Proinflammatory Cytokine, Osteopontin, on Autoimmune Demyelinating Disease" (2003) (117)
Perivascular T Cells Express the Pro‐Inflammatory Chemokine RANTES mRNA in Multiple Sclerosis Lesions (1997) (115)
TCR usage in human and experimental demyelinating disease. (1996) (115)
Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. (2006) (115)
Experimental autoimmune encephalomyelitis in IL-4-deficient mice. (1997) (114)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial (2019) (113)
Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. (2006) (112)
Nanosensor Detection of an Immunoregulatory Tryptophan Influx/Kynurenine Efflux Cycle (2007) (112)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial (2019) (112)
Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: modulation of T cell costimulation. (1999) (111)
Plasmid-Encoded Proinsulin Preserves C-Peptide While Specifically Reducing Proinsulin-Specific CD8+ T Cells in Type 1 Diabetes (2013) (110)
IL-7 Promotes TH1 Development and Serum IL-7 Predicts Clinical Response to Interferon-β in Multiple Sclerosis (2011) (106)
A predominant role of integrin alpha 4 in the spontaneous development of autoimmune diabetes in nonobese diabetic mice. (1994) (106)
Escape from “horror autotoxicus”: Pathogenesis and treatment of autoimmune disease (1995) (105)
Innate and Adaptive Autoimmunity Directed to the Central Nervous System (2009) (105)
Specific HLA-DQB and HLA-DRB1 alleles confer susceptibility to pemphigus vulgaris. (1989) (105)
Interferon-β exacerbates Th17-mediated inflammatory disease. (2011) (104)
Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87–99) (1996) (103)
Systems biology and its application to the understanding of neurological diseases (2009) (103)
Some Misconceptions about Understanding Autoimmunity through Experiments with Knockouts (1997) (102)
Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8 + T cells in type 1 diabetes (2014) (98)
Regulation of disease susceptibility: decreased prevalence of IgE-mediated allergic disease in patients with multiple sclerosis. (1996) (97)
Stress and autoimmunity: the neuropeptides corticotropin-releasing factor and urocortin suppress encephalomyelitis via effects on both the hypothalamic-pituitary-adrenal axis and the immune system. (1997) (96)
A hippocampal protein associated with paraneoplastic neurologic syndrome and small cell lung carcinoma. (1994) (95)
Multiple discrete encephalitogenic epitopes of the autoantigen myelin basic protein include a determinant for I-E class II-restricted T cells (1988) (94)
&agr;B-Crystallin Is a Target for Adaptive Immune Responses and a Trigger of Innate Responses in Preactive Multiple Sclerosis Lesions (2010) (94)
Therapeutic decisions in multiple sclerosis: moving beyond efficacy. (2013) (93)
Type I Interferons: Beneficial in Th1 and Detrimental in Th17 Autoimmunity (2013) (92)
Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. (2007) (91)
Selective and nonselective stages in homing of T lymphocytes to the central nervous system during experimental allergic encephalomyelitis. (1993) (91)
Microarray Profiling of Antibody Responses against Simian-Human Immunodeficiency Virus: Postchallenge Convergence of Reactivities Independent of Host Histocompatibility Type and Vaccine Regimen (2003) (91)
Tryptophan degradation in autoimmune diseases (2007) (91)
An Immunomodulatory GpG Oligonucleotide for the Treatment of Autoimmunity via the Innate and Adaptive Immune Systems 1 (2003) (91)
CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications (2018) (91)
A writing-intensive course improves biology undergraduates' perception and confidence of their abilities to read scientific literature and communicate science. (2013) (88)
Depletion of T-4+ lymphocytes with monoclonal antibody reactivates toxoplasmosis in the central nervous system: a model of superinfection in AIDS. (1987) (87)
Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. (2006) (86)
Reversal of Paralysis and Reduced Inflammation from Peripheral Administration of β-Amyloid in TH1 and TH17 Versions of Experimental Autoimmune Encephalomyelitis (2012) (86)
Modulation of MHC class II antigen expression in human myoblasts after treatment with IFN‐γ (1991) (86)
Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein (2012) (86)
Autoantibody profiling for the study and treatment of autoimmune disease (2002) (85)
Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial (2019) (85)
Photogenerated glycan arrays identify immunogenic sugar moieties of Bacillus anthracis exosporium (2007) (85)
A polyalanine peptide with only five native myelin basic protein residues induces autoimmune encephalomyelitis (1992) (85)
Isolation of a complementary DNA clone encoding an autoantigen recognized by an anti‐neuronal cell antibody from a patient with paraneoplastic cerebellar degeneration (1990) (84)
The Immunobiology of Multiple Sclerosis: An Autoimmune Disease of the Central Nervous System (1999) (84)
Yersinia enterocolitica activates a T helper type 1-like T cell subset in reactive arthritis. (1992) (83)
Late Pregnancy Suppresses Relapses in Experimental Autoimmune Encephalomyelitis: Evidence for a Suppressive Pregancy-Related Serum Factor1 (2002) (83)
Multiple sclerosis: trapped in deadly glue (2005) (83)
Analysis of the T cell repertoire using the PCR and specific oligonucleotide primers. (1992) (83)
Reduced development of COVID-19 in children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics (2020) (83)
Experimental Autoimmune Encephalomyelitis in the Mouse (1994) (82)
γδ T cell receptor repertoire in brain lesions of patients with multiple sclerosis (1993) (82)
Peroxisome proliferator–activated receptor δ limits the expansion of pathogenic Th cells during central nervous system autoimmunity (2010) (81)
Identification of T cell subsets and B lymphocytes in mouse brain experimental allergic encephalitis lesions. (1982) (81)
Protein arrays for autoantibody profiling and fine‐specificity mapping (2003) (81)
Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. (1991) (81)
Optimization of current and future therapy for autoimmune diseases (2012) (80)
Repeated treatment with chimeric anti‐CD4 antibody in multiple sclerosis (1994) (80)
Ia expression in chronic relapsing experimental allergic encephalomyelitis induced by long-term cultured T cell lines in mice. (1986) (78)
A Key Regulatory Role for Histamine in Experimental Autoimmune Encephalomyelitis: Disease Exacerbation in Histidine Decarboxylase-Deficient Mice1 (2006) (78)
Characterization of T‐Cell Receptor αβ Repertoire in Synovial Tissue from Different Temporal Phases of Rheumatoid Arthritis (1992) (78)
Therapeutic Effects of Systemic Administration of Chaperone αB-Crystallin Associated with Binding Proinflammatory Plasma Proteins* (2012) (78)
Proteomics technologies for the study of autoimmune disease. (2002) (76)
N ε ‐(γ‐l‐Glutamyl)‐l‐lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease (2001) (76)
Interleukin-17 Accelerates Allograft Rejection by Suppressing Regulatory T Cell Expansion (2010) (74)
Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens. (2017) (74)
Genetic factors in multiple sclerosis. (1993) (74)
Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis (2016) (73)
Functional rescue of experimental ischemic optic neuropathy with αB-crystallin (2011) (72)
25-Dihydroxyvitamin D 3 Ameliorates Th 17 Autoimmunity via Transcriptional Modulation of Interleukin-17 A (2011) (71)
Immunization with DNA encoding an immunodominant peptide of insulin prevents diabetes in NOD mice. (2001) (70)
Monoclonal anti-I-A antibody reverses chronic paralysis and demyelination in Theiler's virus-infected mice: critical importance of timing of treatment (1987) (70)
Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS. (2002) (70)
Prolactin: a versatile regulator of inflammation and autoimmune pathology. (2015) (69)
Postinfectious and postvaccinial encephalomyelitis. (1984) (69)
Minimum structural requirements for peptide presentation by major histocompatibility complex class II molecules: implications in induction of autoimmunity. (1994) (69)
Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications (2002) (69)
Smad7 in T cells drives T helper 1 responses in multiple sclerosis and experimental autoimmune encephalomyelitis (2010) (68)
A viral peptide with limited homology to a self peptide can induce clinical signs of experimental autoimmune encephalomyelitis. (1998) (68)
Specific T cell receptor gene rearrangements at the site of muscle degeneration in Duchenne muscular dystrophy. (1994) (67)
Inhibition of autoimmune uveitis by anti-CD4 antibody. (1990) (67)
ADP-ribosyltransferase activity of pertussis toxin and immunomodulation by Bordetella pertussis. (1988) (67)
IFN-β Treatment Requires B Cells for Efficacy in Neuroautoimmunity (2015) (66)
Idiotypic immunization induces immunity to mutated p53 and tumor rejection (1998) (66)
T-cell receptor V-gene usage in synovial fluid lymphocytes of patients with chronic arthritis. (1993) (65)
Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS (2012) (64)
Immunity to the Extracellular Domain of Nogo-A Modulates Experimental Autoimmune Encephalomyelitis1 (2004) (64)
Microbial Epitopes Act as Altered Peptide Ligands to Prevent Experimental Autoimmune Encephalomyelitis (1999) (64)
Improved Efficacy of a Tolerizing DNA Vaccine for Reversal of Hyperglycemia through Enhancement of Gene Expression and Localization to Intracellular Sites (2008) (64)
An interferon-β-resistant and NLRP3 inflammasome–independent subtype of EAE with neuronal damage (2016) (64)
Amyloid Fibrils Composed of Hexameric Peptides Attenuate Neuroinflammation (2013) (62)
Selective participation of immunoglobulin V region and major histocompatibility complex products in antigen binding by T cells (1978) (62)
Severe anaphylactic reactions to glutamic acid decarboxylase (GAD) self peptides in NOD mice that spontaneously develop autoimmune type 1 diabetes mellitus (2003) (62)
Diverse T cell receptor V beta gene usage in the central nervous system in experimental allergic encephalomyelitis. (1993) (62)
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. (2007) (62)
HLA-DP beta and susceptibility to multiple sclerosis: an analysis of caucasoid and Japanese patient populations. (1990) (61)
Statins in the treatment of central nervous system autoimmune disease (2006) (60)
Molecular signature of Epstein-Barr virus infection in MS brain lesions (2018) (60)
Bioluminescence in vivo imaging of autoimmune encephalomyelitis predicts disease (2008) (59)
Interferon-gamma-producing T cells, pregnancy, and postpartum relapses of multiple sclerosis. (2010) (59)
Optic Neuritis, A New Variant of Experimental Encephalomyelitis, A Durable Model for All Seasons, Now In Its Seventieth Year (2003) (59)
Tyrosine Kinase Inhibitors Ameliorate Autoimmune Encephalomyelitis in a Mouse Model of Multiple Sclerosis (2011) (59)
The aryl hydrocarbon receptor: a regulator of Th17 and Treg cell development in disease (2008) (58)
Autoimmunity against Fibrinogen Mediates Inflammatory Arthritis in Mice (2009) (58)
IL-17 Contributes to the Development of Chronic Rejection in a Murine Heart Transplant Model (2010) (58)
The development of rational strategies for selective immunotherapy against autoimmune demyelinating disease. (1991) (57)
Local delivery of TNF by retrovirus-transduced T lymphocytes exacerbates experimental autoimmune encephalomyelitis. (1999) (57)
Identification of Naturally Occurring Fatty Acids of the Myelin Sheath That Resolve Neuroinflammation (2012) (57)
αB-crystallin improves murine cardiac function and attenuates apoptosis in human endothelial cells exposed to ischemia-reperfusion. (2011) (57)
Osteopontin polymorphisms and disease course in multiple sclerosis (2003) (57)
Chaperone Activity of Small Heat Shock Proteins Underlies Therapeutic Efficacy in Experimental Autoimmune Encephalomyelitis* (2012) (57)
Innate and Adaptive Autoimmunity Directed to the Central Nervous System (2009) (56)
A neuropeptide in immune-mediated inflammation, Y? (2006) (56)
A Suppressive Oligodeoxynucleotide Enhances the Efficacy of Myelin Cocktail/IL-4-Tolerizing DNA Vaccination and Treats Autoimmune Disease1 (2005) (56)
Major T-cell responses in multiple sclerosis. (1995) (56)
Susceptibility to multiple sclerosis associated with an immunoglobulin gamma 3 restriction fragment length polymorphism. (1987) (56)
Cerebrospinal Fluid Aquaporin-4 Antibody Levels in Neuromyelitis Optica Attacks (2014) (56)
Phase 1 clinical trial of chimeric monoclonal anti‐CD4 antibody in multiple sclerosis (1994) (56)
Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation (2014) (55)
Characterization of T cell lines and clones from SJL/J and (BALB/c x SJL/J)F1 mice specific for myelin basic protein. (1985) (55)
The discovery of natalizumab, a potent therapeutic for multiple sclerosis (2012) (55)
Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1). (2010) (54)
Narcolepsy-cataplexy in Israeli Jews is associated exclusively with the HLA DR2 haplotype. A study at the serological and genomic level. (1988) (54)
Inflammatory Cytokines at the Summits of Pathological Signal Cascades in Brain Diseases (2013) (54)
T cell specificity for class II (I-A) and the encephalitogenic N-terminal epitope of the autoantigen myelin basic protein. (1987) (54)
Non-coding plasmid DNA induces IFN-γ in vivo and suppresses autoimmune encephalomyelitis (1999) (53)
Hyaluronan synthesis is necessary for autoreactive T-cell trafficking, activation, and Th1 polarization (2016) (52)
Expression of granulocyte colony stimulating factor and granulocyte-macrophage colony stimulating factor genes in human astrocytoma cell lines and in glioma specimens (1992) (52)
Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis (2016) (52)
Homologies between T cell receptor junctional sequences unique to multiple sclerosis and T cells mediating experimental allergic encephalomyelitis. (1994) (50)
Inhibition of experimental autoimmune encephalomyelitis by a nonimmunogenic non-self peptide that binds to I-Au. (1992) (50)
Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4 (2016) (49)
Thymic Selection Determines γδ T Cell Effector Fate: Antigen- Naive Cells Make Interleukin-17 and Antigen-Experienced Cells Make Interferon γ (2017) (49)
Pertussis toxin is required for pertussis vaccine encephalopathy. (1985) (49)
Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing– remitting multiple sclerosis (2013) (49)
Gaining entry to an uninflamed brain (2009) (48)
Connections between the immune system and the nervous system. (1993) (48)
Physiological regulation of antigen binding to T cells: role of a soluble macrophage factor and of interferon. (1977) (48)
COVID-19 therapeutics: Challenges and directions for the future (2022) (46)
Protein and peptide array analysis of autoimmune disease. (2002) (46)
The Interdependent, Overlapping, and Differential Roles of Type I and II IFNs in the Pathogenesis of Experimental Autoimmune Encephalomyelitis (2013) (46)
Cerebellar hemorrhage complicating methylmalonic and propionic acidemia. (1984) (45)
The Protective and Therapeutic Function of Small Heat Shock Proteins in Neurological Diseases (2012) (45)
Regulation of different inflammatory diseases by impacting the mevalonate pathway (2009) (45)
Enhanced immune recognition of cryptic glycan markers in human tumors. (2009) (45)
The intricate interplay among body weight, stress, and the immune response to friend or foe. (2003) (43)
IL-2 and TNF receptors as targets of regulatory T-T interactions: isolation and characterization of cytokine receptor-reactive T cell lines in the Lewis rat. (1996) (43)
Mechanisms of anti-CD4-mediated depletion and immunotherapy. A study using a set of chimeric anti-CD4 antibodies. (1990) (43)
Antigen-Specific Therapies in Multiple Sclerosis: Going Beyond Proteins and Peptides (2005) (42)
Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. (2005) (41)
Millennium Award. Proteomics for the development of DNA tolerizing vaccines to treat autoimmune disease. (2002) (41)
Importance of immunoglobulin isotype in therapy of experimental autoimmune encephalomyelitis with monoclonal anti-CD4 antibody. (1987) (41)
Multiplexed autoantigen microarrays identify HLA as a key driver of anti-desmoglein and -non-desmoglein reactivities in pemphigus (2016) (40)
Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS (2017) (40)
Inverse vaccination, the opposite of Jenner’s concept, for therapy of autoimmunity (2010) (40)
Phosphorylation of αB-crystallin supports reactive astrogliosis in demyelination (2017) (39)
Competitive PCR quantification of CD4, CD8, ICAM-1, VCAM-1, and MHC class II mRNA in the central nervous system during development and resolution of experimental allergic encephalomyelitis (1993) (38)
Anorectal incontinence in myotonic dystrophy: a myopathic involvement of pelvic floor muscles. (1992) (38)
Immunotherapy of multiple sclerosis: the end of the beginning. (2001) (38)
Type 1 interferons cool the inflamed brain. (2008) (38)
Prospects for specific immunotherapy in myasthenia gravis (1990) (38)
Socioeconomic Trends in Hospitalization for Multiple Sclerosis (2010) (38)
Prevention of experimental allergic encephalitis with in vivo administration of anti I-A antibody Decreased accumulation of radiolabelled lymph node cells in the central nervous system (1983) (38)
Inhibition of experimental autoimmune thyroiditis in mice by anti-I-A antibodies. (1987) (37)
Successful treatment of EAE in rhesus monkeys with MHC class II specific monoclonal antibodies. (1988) (37)
Presenting an odd autoantigen (1995) (37)
The role of TNFα and lymphotoxin in demyelinating disease (1999) (37)
Polymorphic markers of human T-cell receptor alpha and beta genes. Family studies and comparison of frequencies in healthy individuals and patients with multiple sclerosis and myasthenia gravis. (1988) (36)
Interleukin 17F level and interferon β response in patients with multiple sclerosis. (2013) (36)
Association of susceptibility to multiple sclerosis with TCR genes. (1992) (35)
mir-181a-1/b-1 Modulates Tolerance through Opposing Activities in Selection and Peripheral T Cell Function (2015) (35)
To help aging populations, classify organismal senescence (2019) (35)
Disappearance and reappearance of B cells after in vivo treatment with monoclonal anti-I-A antibodies. (1984) (34)
Homing of Lyt-2+ and Lyt-2- T cell subsets and B lymphocytes to the central nervous system of mice with acute experimental allergic encephalomyelitis. (1984) (34)
Epstein-Barr virus and multiple sclerosis. (2022) (34)
Chaperone Activity of α B-Crystallin Is Responsible for Its Incorrect Assignment as an Autoantigen in Multiple Sclerosis (2011) (34)
Microbial peptides and superantigens in the pathogenesis of autoimmune diseases of the central nervous system. (1998) (34)
Murine model for pertussis vaccine encephalopathy: linkage to H–2 (1982) (34)
Preferential usage of T cell antigen receptor V region gene segment V beta 5.1 by Borrelia burgdorferi antigen-reactive T cell clones isolated from a patient with Lyme disease. (1993) (34)
Administration of myelin basic protein-coupled spleen cells prevents experimental allergic encephalitis. (1983) (34)
Multiple approaches to multiple sclerosis (2000) (34)
Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice (2013) (33)
HMG-CoA reductase inhibition causes increased necrosis and apoptosis in an in vivo mouse glioblastoma multiforme model. (2009) (33)
Absence of “Original Antigenic Sin” in Autoimmunity Provides an Unforeseen Platform for Immune Therapy (1999) (33)
Treatment with a Toll-like receptor inhibitory GpG oligonucleotide delays and attenuates lupus nephritis in NZB/W mice (2010) (33)
Antigen Specific Immunotherapy of Multiple Sclerosis (2001) (32)
Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus. (2008) (32)
Restricted heterogeneity of T cell receptor variable alpha chain transcripts in hearts of Chagas’disease cardiomyopathy patients (1994) (32)
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study (2018) (32)
Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients (2016) (31)
The V-region disease hypothesis: new evidence suggests it is probably wrong. (1993) (31)
Peroxisome proliferator–activated receptor (PPAR)α expression in T cells mediates gender differences in development of T cell–mediated autoimmunity (2007) (31)
The pharmacokinetics and dosing of oral 4‐methylumbelliferone for inhibition of hyaluronan synthesis in mice (2016) (31)
High-throughput Methods for Measuring Autoantibodies in Systemic Lupus Erythematosus and other Autoimmune Diseases (2004) (31)
Genomic and proteomic analysis of multiple sclerosis. Opinion. (2003) (30)
More mayhem from molecular mimics (1997) (30)
Short peptide-based tolerogens without self-antigenic or pathogenic activity reverse autoimmune disease. (1998) (30)
Infection and multiple sclerosis: a possible role for superantigens? (1994) (30)
SEB induced anergy: modulation of immune response to T cell determinants of myoglobin and myelin basic protein. (1993) (29)
Iron‐sulfur glutaredoxin 2 protects oligodendrocytes against damage induced by nitric oxide release from activated microglia (2017) (29)
Drug Insight: using statins to treat neuroinflammatory disease (2005) (29)
Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine (2017) (29)
Multiple sclerosis: From a myelin point of view (1996) (28)
Histamine regulates autoreactive T cell activation and adhesiveness in inflamed brain microcirculation (2011) (28)
Multiple sclerosis: a polygenic disease involving epistatic interactions, germline rearrangements and environmental effects (1997) (28)
Emerging therapeutic targets in multiple sclerosis (2006) (28)
Sequential interaction of macrophages, initiator T lymphocytes and recruited T lymphocytes in a cell‐mediated immune response to soluble antigen (1978) (28)
Regulation of autosensitisation to encephalitogenic myelin basic protein by macrophage-associated and soluble antigen (1977) (28)
N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease. (2001) (28)
Modulation of postoperative cognitive decline via blockade of inflammatory cytokines outside the brain (2010) (28)
MMR Vaccination: A Potential Strategy to Reduce Severity and Mortality of COVID-19 Illness (2020) (27)
Viral damage and the breakdown of self-tolerance (1997) (27)
Time correlation between mononucleosis and initial symptoms of MS (2017) (27)
Restoring immune tolerance in neuromyelitis optica (2016) (27)
Recurrent transverse myelitis, myasthenia gravis, and autoantibodies (1992) (27)
T Cell Receptor BV Gene Rearrangements in the Spinal Cords and Cerebrospinal Fluid of Patients with Amyotrophic Lateral Sclerosis (1999) (27)
Isolated oculomotor palsy after measles immunization. (1980) (27)
Myelin basic protein peptide specificity and T‐cell receptor gene usage of HPRT mutant T‐cell clones in patients with multiple sclerosis (1994) (26)
Gamma delta T cell receptor repertoire in brain lesions of patients with multiple sclerosis. (1993) (26)
Progressive multifocal leukoencephalopathy and multiple sclerosis: Lessons from natalizumab (2006) (25)
Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity (2014) (25)
Neoplastic and reactive human astrocytes express interleukin-8 gene (2004) (25)
Peripheral neuropathy in the cherry‐red spot—myoclonus syndrome (Sialidosis type I) (1980) (25)
Antigen-specific tolerance to self-antigens in protein replacement therapy, gene therapy and autoimmunity. (2019) (25)
Vitamin D, pregnancy, breastfeeding, and postpartum multiple sclerosis relapses. (2011) (25)
The specificity of the antibody response in multiple sclerosis (1998) (25)
Beginning of the end of two-stage theory purporting that inflammation then degeneration explains pathogenesis of progressive multiple sclerosis. (2016) (25)
The role of the MHC and T-cell receptor in susceptibility to multiple sclerosis. (1990) (24)
Common variants in P 2 RY 11 are associated with narcolepsy (2010) (24)
New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis (2020) (24)
Th17 Cells Induce Th1-Polarizing Monocyte-Derived Dendritic Cells (2013) (24)
The gender gap in multiple sclerosis: intersection of science and society. (2013) (24)
Monoclonal anti-Ia antibody therapy in animal models of autoimmune disease. (1987) (24)
Clinical optimization of antigen specific modulation of type 1 diabetes with the plasmid DNA platform. (2013) (24)
DNA vaccination in the treatment of autoimmune disease. (2000) (24)
Autoantibodies against central nervous system antigens in a subset of B cell–dominant multiple sclerosis patients (2020) (24)
Tissue Transglutaminase contributes to experimental multiple sclerosis pathogenesis and clinical outcome by promoting macrophage migration (2015) (24)
The potential therapeutic role of statins in central nervous system autoimmune disorders (2003) (23)
Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients (1991) (23)
Mechanism of metabolic stroke and spontaneous cerebral hemorrhage in glutaric aciduria type I (2014) (23)
Part II. high-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced ‘PANIC’1 attack (2020) (23)
An analysis of T‐cell‐receptor variable‐region genes in tumor‐infiltrating lymphocytes within malignant tumors (1991) (22)
State of the art. Four easy pieces: interconnections between tissue injury, intermediary metabolism, autoimmunity, and chronic degeneration. (2006) (22)
Increased incidence of certain TCR and HLA genes associated with myasthenia gravis in Italians. (1990) (22)
The re-emergence of antigen-specific tolerance as a potential therapy for MS (2015) (22)
DNA threads released by activated CD4+ T lymphocytes provide autocrine costimulation (2019) (22)
Suppression of experimental uveitis in rats by anti-I-A antibodies. (1989) (21)
Interaction of the pertussis toxin peptide containing residues 30-42 with DR1 and the T-cell receptors of 12 human T-cell clones. (1992) (21)
Shifting therapeutic attention in MS to osteopontin, type 1 and type 2 IFN (2009) (21)
Restoring immune tolerance in neuromyelitis optica (2016) (21)
Gene microarrays and experimental demyelinating disease: a tool to enhance serendipity. (2001) (21)
No quiet surrender: molecular guardians in multiple sclerosis brain. (2015) (21)
Antigen-specific therapy of multiple sclerosis: The long-sought magic bullet (2007) (20)
Nogo in multiple sclerosis: Growing roles of a growth inhibitor (2006) (20)
Usage of T cell receptor beta-chain variable gene is highly restricted at the site of inflammation in murine autoimmune uveitis. (1993) (20)
Critical role for prokineticin 2 in CNS autoimmunity (2015) (20)
Approved and Future Pharmacotherapy for Multiple Sclerosis (2002) (20)
Genetic control of susceptibility to experimental allergic neuritis and the immune response to P2 protein (1981) (19)
Tolerizing DNA vaccines for autoimmune arthritis (2006) (19)
HTLV‐I sequences are not detected in peripheral blood genomic DNA or in brain cDNA of multiple sclerosis patients (1990) (19)
The epigenetics of multiple sclerosis: clues to etiology and a rationale for immune therapy. (1994) (19)
Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease (2015) (19)
The Neuropathology of Propionic Acidemia (1983) (19)
Identification of a common immune regulatory pathway induced by small heat shock proteins, amyloid fibrils, and nicotine (2018) (18)
The gray aspects of white matter disease in multiple sclerosis (2009) (18)
The role of TNFalpha and lymphotoxin in demyelinating disease. (1999) (18)
Specificity of antigen binding by T cells; competition between soluble and Ia‐associated antigen (1981) (18)
From defining antigens to new therapies in multiple sclerosis: honoring the contributions of Ruth Arnon and Michael Sela. (2014) (18)
Bench to Bedside and Beyond (2016) (18)
Reinduction of experimental autoimmune encephalomyelitis in mice. (1995) (18)
Part I. SARS-CoV-2 triggered ‘PANIC’1 attack in severe COVID-19 (2020) (17)
Autoimmune Comorbid Conditions in Multiple Sclerosis (2011) (17)
Selection ofhprtMutant T Cells as Surrogates for Dividing Cells Reveals a Restricted T Cell Receptor BV Repertoire in Insulin-Dependent Diabetes Mellitus (1999) (17)
MHC-restricted recognition of immunogenic T cell epitopes of pertussis toxin reveals determinants in man distinct from the ADP-ribosylase active site (1988) (17)
Human aquaporin 4281-300 is the immunodominant linear determinant in the context of HLA-DRB1*03:01: relevance for diagnosing and monitoring patients with neuromyelitis optica. (2012) (17)
Gaps in knowledge and prospects for research of adjuvanted vaccines. (2015) (17)
Blockade of gamma interferon might be beneficial in MS (2001) (17)
Immunopathogenesis of human inflammatory arthritis: lessons from Lyme and reactive arthritis. (1994) (17)
Mechanistic insights into influenza vaccine-associated narcolepsy (2016) (17)
Engineered DNA plasmid reduces immunity to dystrophin while improving muscle force in a model of gene therapy of Duchenne dystrophy (2018) (17)
Lessons learned at the intersection of immunology and neuroscience. (2012) (16)
Evolution of MS lesions to black holes under DNA vaccine treatment (2012) (16)
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. (2013) (16)
Adrenocorticotropic hormone versus methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial (2017) (16)
Despite epitope spreading in the pathogenesis of autoimmune disease, highly restricted approaches to immune therapy may still succeed [with a hedge on this bet]. (2000) (16)
Weighing In On Autoimmune Disease: 'Hub-and-spoke' T cell traffic in autoimmunity (2013) (16)
CD4+CD25+ Regulatory T Cells Specific for a Thymus-Expressed Antigen Prevent the Development of Anaphylaxis to Self1 (2008) (16)
The polymerase chain reaction for detection of T-cell antigen receptor expression (1992) (16)
Inhibition of T cell proliferation specific for acetylcholine receptor epitopes related to myasthenia gravis with antibody to T cell receptor or with competitive synthetic polymers. (1990) (16)
Non-coding plasmid DNA induces IFN-gamma in vivo and suppresses autoimmune encephalomyelitis. (1999) (16)
Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches (2021) (15)
Statins as potential therapeutic agents in multiple sclerosis (2004) (15)
Thymic Epithelium Determines a Spontaneous Chronic Neuritis in Icam1tm1JcgrNOD Mice (2014) (15)
Statins—Treatment option for central nervous system autoimmune disease? (2007) (15)
The polymerase chain reaction for detection of T-cell antigen receptor expression. (1992) (15)
T-cell receptor V beta gene expression differs in tumor-infiltrating lymphocytes within primary and metastatic melanoma. (1991) (15)
Conflicting consequences of immunity to cancer versus autoimmunity to neurons: Insights from paraneoplastic disease (2014) (15)
Characterization of T-cell receptor alpha beta repertoire in synovial tissue from different temporal phases of rheumatoid arthritis. (1992) (15)
Multiple sclerosis and its animal models: the role of the major histocompatibility complex and the T cell receptor repertoire (2004) (15)
Comparison of rat and rat-mouse chimeric anti-murine CD4 antibodies in vitro. Chimeric antibodies lyse low-density CD4+ cells. (1989) (14)
Cyclic adenosine 3',5'-monophosphate metabolism in activated T-cell clones. (1989) (14)
CD45 isoforms on human CD4+ T-cell subsets. (1996) (14)
The road not taken: antigen-specific therapy and neuroinflammatory disease. (2013) (14)
New targets for treatment of multiple sclerosis (2008) (14)
At once harmful and beneficial: the dual properties of NF-κB (2006) (14)
CRYAB modulates the activation of CD4+ T cells from relapsing–remitting multiple sclerosis patients (2013) (14)
Protective and Therapeutic Role for α B-Crystallin in Autoimmune Demyelination (2007) (14)
The Safety of Adjuvanted Vaccines Revisited: Vaccine-Induced Narcolepsy. (2016) (14)
Immunomodulation of Experimental Autoimmune Encephalomyelitis with Ordered Peptides Based on MHC-TCR Binding Motifs1 (2001) (14)
What went wrong in the natalizumab trials? (2006) (14)
Uncovering Cryptic Glycan Markers in Multiple Sclerosis (MS) and Experimental Autoimmune Encephalomyelitis (EAE) (2014) (14)
Characterization of acute bone marrow graft rejection in T cell-depleted, partially mismatched related donor bone marrow transplantation. (1995) (14)
Smad 7 in T cells drives T helper 1 responses in multiple sclerosis and experimental autoimmune encephalomyelitis (2010) (13)
Comparison of antigen specificity, class II major histocompatibility complex restriction, and in vivo behavior of myelin basic protein-specific T cell lines and clones derived from (BALB/c x SJL/J) mice. (1987) (13)
Progression in multiple sclerosis is associated with low endogenous NCAM (2013) (13)
The environment strikes back. (1993) (13)
Therapy of Autoimmune Diseases with Antibody to Immune Response Gene Products or to T‐Cell Surface Markers a (1986) (13)
A rush to judgment on Th 17 (13)
Cell adhesion molecules: a selective therapeutic target for alleviation of IDDM. (1994) (13)
Genomic and proteomic analysis of multiple sclerosis (2003) (13)
Induction of New Autoimmune Diseases After Alemtuzumab Therapy for Multiple Sclerosis: Learning From Adversity. (2017) (13)
Polymorphic residues on the I-A beta chain modulate the stimulation of T cell clones specific for the N-terminal peptide of the autoantigen myelin basic protein. (1989) (12)
Platelets provide a bounty of potential targets for therapy in multiple sclerosis. (2012) (12)
Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. (2021) (12)
Janus Faces of Amyloid Proteins in Neuroinflammation (2014) (12)
Exploring the potential of DNA vaccination. (1997) (12)
At once harmful and beneficial: the dual properties of NF-kappaB. (2006) (12)
Mechanisms of action of therapeutic amyloidogenic hexapeptides in amelioration of inflammatory brain disease (2014) (12)
T‐Cell Receptor Gene Usage of Acetylcholine Receptor‐specific T‐Helper Cells (1993) (12)
Interim results of a phase I/II clinical trial of a DNA plasmid vaccine (BHT-3021) for type 1 diabetes (2009) (12)
Supplementary Materials for Plasmid-Encoded Proinsulin Preserves C-Peptide While Specifically Reducing Proinsulin-Specific CD8 + T Cells in Type 1 Diabetes (2013) (12)
PREDOMINANT EXPRESSION OF A T CELL RECEPTOR V,6 GENE SUBFAMILY IN AUTOIMMUNE ENCEPHALOMYELITIS (2003) (12)
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. (2022) (11)
Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy (2005) (11)
Multiple T and B cell epitopes in the S1 subunit ("A"-monomer) of the pertussis toxin molecule. (1989) (11)
New allelic polymorphisms in TAP genes (2004) (11)
Mitigating alemtuzumab-associated autoimmunity in MS (2020) (11)
Isolation of a complementary DNA clone encoding an autoantigen recognized by an anti-neuronal cell antibody from a patient with paraneoplastic cerebellar degeneration. (1991) (11)
Cytokines in multiple sclerosis (1996) (11)
Altered Peptide Ligands and MS Treatment (2002) (11)
The multifaceted role of transglutaminase in neurodegeneration: Review article (2004) (11)
Prospects for Immunotherapy Directed to the T Cell Receptor in Human Autoimmune Disease a (1991) (11)
Multiple sclerosis. Presenting an odd autoantigen. (1995) (11)
Statins and their potential targets in multiple sclerosis therapy (2003) (10)
Oligonucleotide dot-blot analysis of HLA-DQβ alleles associated with multiple sclerosis (1991) (10)
Pathogen antigen- and superantigen-reactive synovial fluid T cells in reactive arthritis. (1995) (10)
Anti-inflammatory strategies for the treatment of multiple sclerosis – tryptophan catabolites may hold the key (2006) (10)
Autoimmune disease. (1993) (10)
EAE: a model for immune intervention with synthetic peptides. (1992) (10)
The coming of age for antigen‐specific therapy of multiple sclerosis (2006) (10)
Evaluating Human T Cell Receptor Gene Expression by PCR (1997) (10)
> B-Crystallin Is a Target for Adaptive Immune Responses and a Trigger of Innate Responses in Preactive Multiple Sclerosis Lesions (2010) (10)
The use of monoclonal antibodies for treatment of autoimmune disease (1990) (9)
Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials (2021) (9)
Engineering better cytokines (2003) (9)
Development of Th17‐Associated Interstitial Kidney Inflammation in Lupus‐Prone Mice Lacking the Gene Encoding STAT‐1 (2015) (9)
Piet Mondrian’s trees and the evolution in understanding multiple sclerosis, Charcot Prize Lecture 2011 (2013) (9)
HLA‐DQ Restriction Fragment Length Polymorphisms in Myasthenia Gravis a (1987) (9)
Type II HMG-CoA Reductase Inhibitors (Statins) Provide Acute-Graft-Versus-Host Disease Protection by Th-2 Cytokine Induction While Sparing Graft-Versus-Leukemia Activity. (2006) (9)
Immunogenetics of autoimmune disease (1989) (9)
Human peptidome display (2011) (9)
Statins and their potential targets in multiple sclerosis therapy. (2003) (9)
PH20 is not expressed in murine CNS and oligodendrocyte precursor cells (2017) (9)
Ozanimod Demonstrates Efficacy and Safety in a Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase 3 Trial of Relapsing Multiple Sclerosis (SUNBEAM) (P3.396) (2018) (8)
T cell recognition in experimental autoimmune encephalomyelitis: prospects for immune intervention with synthetic peptides. (1990) (8)
Systems biology for identification of molecular networks in multiple sclerosis (2009) (8)
Anti-Insulin Immune Responses Are Detectable in Dogs with Spontaneous Diabetes (2016) (8)
Combining statins with interferon beta in multiple sclerosis: think twice, it might not be all right (2011) (8)
Narcolepsy and influenza vaccination-induced autoimmunity. (2017) (8)
T Cell–Transfer Experimental Autoimmune Encephalomyelitis: Pillar of Multiple Sclerosis and Autoimmunity (2017) (8)
T-Cell Receptor Repertoire Vβ in Alopecia Areata (1995) (8)
CEACAM1 mediates B cell aggregation in central nervous system autoimmunity (2016) (8)
Identification of Candidate Tolerogenic CD8+ T Cell Epitopes for Therapy of Type 1 Diabetes in the NOD Mouse Model (2016) (8)
Development of therapies for autoimmune disease at Stanford: a tale of multiple shots and one goal (2014) (8)
Selection of hprt mutant T cells as surrogates for dividing cells reveals a restricted T cell receptor BV repertoire in insulin-dependent diabetes mellitus. (1999) (8)
Restoring immune tolerance in neuromyelitis optica: Part I (2018) (8)
Anaphylaxis to a self-peptide in the absence of mast cells or histamine (2009) (8)
Nonclassical monocytes: are they the next therapeutic targets in multiple sclerosis? (2018) (7)
Treatment of Experimental Autoimmune Myasthenia Gravis with Monoclonal Antibodies to Immune Response Gene Products a (1987) (7)
CD4 cell response to interval therapy with natalizumab (2015) (7)
Small Heat Shock Proteins, Amyloid Fibrils, and Nicotine Stimulate a Common Immune Suppressive Pathway with Implications for Future Therapies. (2018) (7)
Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4 (2017) (7)
Medicine: Collateral damage repaired (2003) (7)
Re‐engineering of pathogenic aquaporin 4‐specific antibodies as molecular decoys to treat neuromyelitis optica (2012) (7)
Calibration of cell-intrinsic interleukin-2 response thresholds guides design of a regulatory T cell biased agonist (2021) (7)
Day hospital treatment of acute psychiatric illness. (1962) (7)
Suppression of autoimmunity via microbial mimics of altered peptide ligands. (2005) (7)
Treatment with anti-FcεRIα antibody exacerbates EAE and T-cell immunity against myelin (2017) (7)
Gene expression analysis of histamine receptors in peripheral blood mononuclear cells from individuals with clinically-isolated syndrome and different stages of multiple sclerosis (2014) (7)
Evolution, function, and utilization of major histocompatibility complex polymorphism in autoimmune disease. (1989) (7)
Trimolecular interactions in experimental autoimmune demyelinating disease and prospects for immunotherapy. (1991) (7)
Murine model for pertussis vaccine encephalopathy: role of the major histocompatibility complex; antibody to albumin and to Bordetella pertussis and pertussis toxin. (1985) (6)
Natural occurrence of thymocytes that react with myelin basic protein (1980) (6)
Antigen-specific immunomodulation in multiple sclerosis patients treated with MBP encoding DNA plasmid (BHT-3009) alone or combined with atorvastatin (2006) (6)
From treatment of experimental allergic encephalomyelitis to clinical trials in multiple sclerosis. (1993) (6)
Self-Assembling Peptides Form Immune Suppressive Amyloid Fibrils Effective in Autoimmune Encephalomyelitis. (2015) (6)
Superantigens in demyelinating disease (2004) (6)
Axonal and Myelin Neuroprotection by the Peptoid BN201 in Brain Inflammation (2019) (6)
Controlling autoimmunity in sporadic inclusion-body myositis (2006) (6)
Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies (2021) (6)
Erratum: Depleting tumor-specific Tregs at a single site eradicates disseminated tumors (Journal of Clinical Investigation (2013) 123:11 (4980) DOI:10.1172/JCI73340) (2013) (5)
The unexpected benefit of stealth (1992) (5)
Response to comment on “Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2” (2015) (5)
Mitigating alemtuzumab-associated autoimmunity in MS: A "whack-a-mole" B-cell depletion strategy (2021) (5)
Specific motifs in T cell receptor VβDβJβ gene sequences in multiple sclerosis lesions in brain (1994) (5)
The Polymerase Chain Reaction and the Analysis of the t Cell Receptor Repertoire (1992) (5)
New approaches to the therapy of demyelinating disease (1991) (5)
Restricted T-cell receptor usage in spinal cord and brain of patients with amyotrophic lateral sclerosis (1991) (5)
, remitting multiple sclerosis − relapsing Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from (2013) (5)
Erratum: Common variants in P2RY11 are associated with narcolepsy (2011) (5)
Myelin-specific CD 8 T Cells in the Pathogenesis of Experimental Allergic Encephalitis and Multiple Sclerosis (2001) (5)
Risk of severe COVID-19 infection among adults with prior exposure to children (2022) (5)
Immunogenetic mechanisms in myasthenia gravis. (1990) (5)
Prevention of EAE with monoclonal anti-I-A antibodies. (1981) (4)
Development of antigen-specific therapies for autoimmune disease. (1990) (4)
The sites of synthesis and the subsequent migration of newly synthesized protein in retina. (1974) (4)
Autoimmune Diseases: The Role for Vaccines (2020) (4)
New approaches to therapy of autoimmune disease. (1985) (4)
'Lupus-prone' mice are susceptible to organ-specific autoimmune disease, experimental allergic encephalomyelitis. (1994) (4)
Erratum: Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine (Nature Medicine (2002) 8 (143-149)) (2002) (4)
Immunomodulatory vaccination in autoimmune disease. (2002) (4)
Safety of Ozanimod Versus Interferon β-1a in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) (S36.006) (2018) (4)
[An analysis of lymphokine gene expression within astrocytoma]. (1992) (4)
Genome-wide RNA expression profiling in human grey and white matter tissue reveals a role for PSA-NCAM dysregulation in MS pathogenesis (2014) (4)
Genetic background modulates outcome of therapeutic amyloid peptides in treatment of neuroinflammation (2016) (4)
A century of pavlovian experiments forming a circuit from the elucidation of neural reflexes to pharmaceuticals and electroceuticals to treat diseases (2015) (3)
Multiple sclerosis and gene expression profiling. (2001) (3)
The Fourth Bioelectronic Medicine Summit “Technology Targeting Molecular Mechanisms”: current progress, challenges, and charting the future (2021) (3)
Unprimed spleen cell populations recognize macrophage-bound antigen with opposite net electric charge. (1977) (3)
Editorial overview Genetic dissection of tolerance (1992) (3)
Role reversal: infiltrating T cells protect the brain. (2015) (3)
Histamine in Immune Regulation: Possible Roles in Autoimmune Demyelinating Disease of the Central Nervous System (2005) (3)
Unique T‐Cell Receptor Junctional Sequences Found in Multiple Sclerosis and T‐Cells Mediating Experimental Allergic Encephalomyelitis a (1995) (3)
Autoimmune disease and the nervous system. (1992) (3)
MILLENNIUM AWARD RECIPIENT CONTRIBUTION Proteomics for the Development of DNA Tolerizing Vaccines to Treat Autoimmune Disease (2002) (3)
Specific motifs in T cell receptor V beta D beta J beta gene sequences in multiple sclerosis lesions in brain. (1994) (3)
A sugar‐coated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD‐19 (2020) (3)
A scientific sequel to Stieg Larsson: relationship between Pandemrix – pandemic influenza vaccine – and the subsequent development of narcolepsy (2014) (3)
Autoimmune demyelinating disease. (1989) (3)
An amyloidogenic hexapeptide derived from amylin attenuates inflammation and acute lung injury in murine sepsis (2018) (3)
Going viral and the fatal vulnerability of neurons from immunity, not from infection (2014) (3)
Clinical and Magnetic Resonance Imaging Results From RADIANCE Part B, a Multicenter, Randomized, Double-Blind, Phase 3 Trial of Ozanimod Versus Intramuscular Interferon β-1a in Relapsing Multiple Sclerosis (RMS) (P3.410) (2018) (3)
Correction: Peroxisome proliferator–activated receptor (PPAR)α expression in T cells mediates gender differences in development of T cell–mediated autoimmunity (2018) (3)
Neurofilament Light Chains as a Marker of Concurrent and Future Active Disease in Relapsing Multiple Sclerosis: An Analysis of Baseline Data From the Phase 3 Ozanimod Clinical Trials (S56.006) (2019) (2)
Antigen-specific suppressor cells in experimental autoimmune uveitis. (1992) (2)
Phase IIb trial of a MBP encoding DNA plasmid ( BHT - 3009) for the treatment of relapsing - remmitting multiple sclerosis (2007) (2)
Gene specific and antigen specific strategies for the induction of suppressor T cells to myelin basic protein. (1984) (2)
The emergence of neuroepidemiology, neurovirology and neuroimmunology: the legacies of John F. Kurtzke and Richard ‘Dick’ T. Johnson (2017) (2)
Therapy of autoimmune disease with monoclonal antibodies to class II gene products of the major histocompatibility complex. (1988) (2)
Designing rational therapies for multiple sclerosis (1995) (2)
Targeting molecules involved in immune cell trafficking to the central nervous system for therapy in multiple sclerosis (2017) (2)
T-cell receptor repertoire V beta in alopecia areata. (1995) (2)
Delivery of myelin peptides through the first line of defense, skin, to counter autoimmunity in multiple sclerosis (2010) (2)
Roep Reducing Proinsulin-Specific CD 8 + T Cells in Type 1 Diabetes Plasmid-Encoded Proinsulin Preserves C-Peptide While Specifically (2013) (2)
Homing of lymphoid populations in EAE. (1984) (2)
[Expression of cytokine genes within astrocytoma cell lines and brain specimens]. (1991) (2)
Treatment of EAE by Anti-MHC Class II-Specific Monoclonal Antibodies in Rhesus Monkeys (1989) (2)
The right stuff: Breaking through the xenotransplant barrier (1996) (2)
Inverse Vaccination to Silence Immunity to Myelin in Multiple Sclerosis (2010) (2)
Multiple sclerosis: From immunogenetics to immunotherapy (1993) (2)
Blocking immune intrusion into the brain suppresses epilepsy in Rasmussen’s encephalitis model (2018) (2)
T cell receptors in autoimmune disease as targets for immune intervention. (1989) (2)
Why are prions and amyloid structures immune suppressive and other intriguing questions facing neuroimmunologists in the future. (2014) (2)
Multiple sclerosis (PP-038) (2010) (1)
Neither T-helper type 2 nor Foxp3+regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity (2014) (1)
T-CELL RECEPTOR REPERTOIRE VBETA IN ALOPECIA AREATA (1995) (1)
Parsing Physiological Functions of Erythropoietin One Domain at a Time (2015) (1)
Characterization of HLA-DRβ and HLA DQβ Alleles Associated with Pemphigus Vulgaris (1989) (1)
Non-toxigenic mutants of "Bordetella pertussis". (1986) (1)
Suppressive Role of CD72 in Experimental Autoimmune Encephalomyelitis (128.22) (2007) (1)
IL-17 in Colonic Epithelial Cells Differential Regulation of Chemokines (2008) (1)
A Tip leads cytotoxic T cells to the crime scene in neuroinflammation (2013) (1)
T cell receptor usage in brains of multiple sclerosis patients. Correlation with HLA class II molecular phenotype (1991) (1)
NAD+ metabolism drives astrocyte proinflammatory reprogramming in central nervous system autoimmunity (2022) (1)
Regulation of antigen binding to T cells: the role of products of adherent cells, and the H-2 restriction of the antigen bound. (1979) (1)
Increasing GABA Activity Prevents Autoimmune Neuroinflammation (2007) (1)
Autoimmune Disease Self-Antigenic or Pathogenic Activity Reverse Short Peptide-Based Tolerogens Without (1998) (1)
Peripheral T-Cells, B-Cells, and Monocytes from Multiple Sclerosis Patients Supplemented with High-Dose Vitamin D Show Distinct Changes in Gene Expression Profiles (2022) (1)
Role of MHC Polymorphism in Autoimmune Disease (1989) (1)
OR.54. Inhibitory Role for γ-Aminobutyric Acid in Autoimmune Inflammation (2009) (1)
Genetic dissection of tolerance. (1992) (1)
Pathogenic T helper 1 cells reach the brain before T helper 17 cells, and T regulatory cells suppress them albeit incompletely (2013) (1)
Experiments on the physiological regulation of the H-2 complex☆☆☆ (1976) (1)
Experimental encephalomyelitis at age 90, still relevant and elucidating how viruses trigger disease (2023) (1)
T.114. Interim Results of a Phase I/II Clinical Trial of a DNA Plasmid Vaccine (BHT-3021) for Type 1 Diabetes (2009) (1)
Letters to the editor (1992) (1)
The role of CTSH in narcolepsy susceptibility and autoimmunity (47.16) (2011) (1)
A Journey in Science: The Privilege of Exploring the Brain and the Immune System (2016) (1)
Autoimmunity and the nervous system (1988) (1)
Combined influence of HLA DR2, DRw4 and T cell receptor genes on the susceptibility of multiple sclerosis (1991) (1)
Response to Comment on “Chaperone Activity of α B-Crystallin Is Responsible for Its Incorrect Assignment as an Autoantigen in Multiple Sclerosis” (2011) (1)
The inherent challenges of classifying senescence—Response (2020) (1)
Multiplex autoantibody profiling using 'synovial proteome' microarrays identifies citrulline-modified peptides as major targets of the autoimmune response in rheumatoid arthritis (2003) (1)
Immunologic basis for functional recovery in neurologic diseases. (1988) (1)
Efficacy of Ozanimod Versus Interferon β-1a by Prior Treatment and Baseline Disability in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) (S36.005) (2018) (1)
Genetic influences on neuroimmunologic disease. (1990) (1)
The induction and regulation of inflammation: new molecular players IP28. Heat Shock Proteins: Darwinistic Immune Modulation on Dangerous Grounds (2011) (1)
Ublituximab versus teriflunomide in relapsing MS patients (2022) (1)
Mechanism of metabolic stroke and spontaneous cerebral hemorrhage in glutaric aciduria type I (2014) (1)
Systems Biology for the Study of Multiple Sclerosis (2013) (1)
T cell receptor variability in myasthenia gravis (1991) (1)
Coccidioidal antigen reactive CD4+ T-lymphocytes in the cerebrospinal fluid in coccidioides immitis meningitis. (1995) (1)
Improvement of Comorbid Psoriasis in Patients With MS Treated With Natalizumab (2021) (1)
FOXP3+ regulatory T cells use heparanase to access IL-2 bound to ECM in inflamed tissues (2023) (0)
Parsing Physiological Functions of Erythropoietin One Domain at a Time (2015) (0)
The role of hyaluronan and 4-methylumbelliferone treatment in multiple sclerosis (2014) (0)
Chapter 4 . 2 Pathway analysis of microRNA expression in multiple sclerosis lesions (2012) (0)
Development of Anaphylaxis to Self a Thymus-Expressed Antigen Prevent the Regulatory T Cells Specific for + CD 25 + CD 4 Mantegazza and Rosetta (2008) (0)
VLA-4 β1 integrin is involved in leucocyte binding to brain endothelium in experimental autoimmune encephalomyelitis (1991) (0)
Immune Responses of Patients with Myasthenia Gravis to Peptides Representing Different Regions of the Human Acetylcholine Receptor (1989) (0)
T-cell receptor V. and Ca alleles associated with multiple sclerosis and myasthenia gravis (0)
POLYMORPHISM IN MS. REPLY (1992) (0)
T cell receptor and autoimmune disease. (1990) (0)
REGULATION OF AUTOIMMUNITY BY THE MODE OF PRESENTATION OF AUTOANTIGEN TO LYMPHOCYTES (1977) (0)
335: Inhibition of HMG-CoA reductase activity with statins provides acute-graft-versus-host disease protection by Th-2 cytokine induction while sparing graft-versus-leukemia activity (2007) (0)
Multiple sclerosis woes (2005) (0)
Ublituximab Efficacy in Treatment-Naive Participants With Relapsing Multiple Sclerosis in the Phase 3 ULTIMATE I and II Studies (P6-3.015) (2023) (0)
Risk Factors and Outcomes in Patients With Coronary Artery Aneurysms (2004) (0)
Suppressive Pregancy-Related Serum Factor Encephalomyelitis: Evidence for a Experimental Autoimmune Late Pregnancy Suppresses Relapses in (2002) (0)
Protein microarray characterization of autoantibody responses in rheumatoid arthritis and systemic lupus erythematosus (2002) (0)
Amyloid Fibril-Forming Hexapeptides Modulate The Immune Response And Reduce Symptoms In An Animal Model Of Multiple Sclerosis (S14.002) (2014) (0)
Startups on the menu: Atreca (2014) (0)
Nostalgia: the similarities between immunological and neurological memory (2012) (0)
The use of monoclonal antibodies for treatment of autoimmune disease. Discussion (1990) (0)
Decreased miR-219 expression in MS: Clinical implications? (2014) (0)
Distinctive and Cooperative Role of Type I and Type II Interferons in the Pathogenesis of TH1 and TH17 Cells in Autoimmune Neuroinflammation (2010) (0)
Microsoft Word-JBC resubmittal Dec 28.docx (2011) (0)
Correction: Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein (1998) (0)
Targeting deoxycytidine kinase improves symptoms in mouse models of multiple sclerosis (2022) (0)
Neurotrophins : brain-derived neurotrophic factor and nerve growth factor (0)
Signal transduction blockade with imatinib mesylate prevents and treats autoimmune arthritis (B76) (2007) (0)
Sa.41. Pathways of Anaphylaxis to Self Myelin Peptides in Mice (2006) (0)
Methacholine Inhalation Challenge for Diagnosis of Asthma ASTHMA (0)
Sa.18. PPARα Mediates the Sexual Dimorphism in the Development of Th1-Mediated CNS Autoimmune Disease (2006) (0)
Axonal and Myelin Neuroprotection by the Peptoid BN201 in Brain Inflammation (2019) (0)
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial (2022) (0)
Cystic fibrosis deadlier for Hispanics than non-Hispanics (2015) (0)
Autoimmunity: 2000 and Beyond, Newport Beach, California, February 11–13, 2000 (2004) (0)
MHC in immunobiology and neuroimmunology (1991) (0)
Afewautoreactive cells inanautoimmune infiltrate control avast population ofnonspecific cells: Atale ofsmartbombsand theinfantry (1996) (0)
Molecular approaches toward a therapy for multiple sclerosis. (1987) (0)
The RADIANCE and SUNBEAM phase 3 studies of ozanimod in relapsing multiple sclerosis: study design and baseline characteristics (P6.344) (2017) (0)
T.77. Tyrosine Kinases in Autoimmune Demyelination (2009) (0)
Exome Sequencing Unravels Novel Candidate Genes in Familial Multiple Sclerosis (P2.219) (2015) (0)
Innate and Adaptive Autoimmunity Directed to the Central Nervous System (2009) (0)
Autoimmunity: 2000 and Beyond, Newport Beach, California, February 11–13, 2000 (2004) (0)
Specific Immunotherapeutic Strategies: Lessons from Myelin Basic Protein-Induced Experimental Allergic Encephalomyelitis (1992) (0)
Regulation of selection and autoimmunity by miR-181 family miRNAs (123.36) (2012) (0)
Macrophage-derived tissue Transglutaminase contributes to experimental multiple sclerosis pathogenesis and clinical outcome (2015) (0)
Development of therapies for autoimmune disease at Stanford: a tale of multiple shots and one goal (2014) (0)
CostimulationAutoimmune Disease: Modulation of T Cell Encoding a Self-Peptide Prevents Suppressive Immunization with DNA (1999) (0)
State of the Art. Four Easy Pieces (2012) (0)
timing of treatment. virus-infected mice: critical importance of paralysis and demyelination in Theiler's Monoclonal anti-I-A antibody reverses chronic (2013) (0)
I Reseptordeterminanter anti-t-celler Foer Treatment of autoimmune disease. (1989) (0)
Platform Presentations (2002) (0)
Gene expression analysis of histamine receptors in peripheral blood mononuclear cells from clinically-isolated syndrome and multiple sclerosis patients (2014) (0)
Differential phosphorylation of alpha B-crystallin in astrocytes and oligodendrocytes suggests a diversity in its biological function (2014) (0)
Compositions for use in a method for treating a patient suffering from multiple sclerosis People (1991) (0)
Polymorphism in MS (1992) (0)
Neuropeptides induce secretion of cytokines from antigen-specific T-cells, and break their commitment to a distinct Th1 or Th2 phenotype (1998) (0)
Blocking protein expression delays onset of paralysis in mice with a form of multiple sclerosis , study finds (2013) (0)
T-cell infiltration in the muscles of boys with Duchenne muscular dystrophy pre and post transfer of normal myoblasts (1991) (0)
In vivo effects of anti-i-a antibody: reduction of t-cell proliferative and antibody responses to acetylcholine receptor. Abstr. (1982) (0)
Autoimmune Encephalomyelitis 17 Versions of ExperimentalH 1 and TH-Amyloid in T β Administration of Reversal of Paralysis and Reduced Inflammation from Peripheral (2012) (0)
Correlations Between Early MRI Parameters and Long-term Clinical Outcomes in Phase 3 and Open-label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis (P5-3.010) (2023) (0)
scienceto read scientific literature and communicate undergraduates' perception and confidence of their A writing-intensive course improves biology (2016) (0)
T CELL RECEPTORS IN (1989) (0)
T cell receptor tcr usage in brains of multiple sclerosis patients (1992) (0)
OR.51. Blocking Serotonin Reuptake Ameliorates Autoimmune Neuroinflammation (2008) (0)
Autoimmunity: 2000 and Beyond, Newport Beach, California, February 11–13, 2000 (2004) (0)
MYC-induced lymphomagenesis Inhibition of HMGcoA reductase by atorvastatin prevents and reverses (2013) (0)
Duchenne muscular rearrangements at the site of muscle Specific T cell receptor gene (2001) (0)
T Cell Adhesion to Fibronectin Neuropeptides, Via Specific Receptors, Regulate (0)
Detection of Vγ and V° transcripts in multiple sclerosis lesions (1991) (0)
Reversal of Misfortune: Therapeutic Strategies on the Horizon (2016) (0)
EncephalomyelitisPathogenesis of Experimental Autoimmune the Differential Roles of Type I and II IFNs in The Interdependent, Overlapping, and (2013) (0)
Book reviews (1982) (0)
Lymphocyte and Eosinophil Responses in Healthy Subjects Dosed with Tecfidera® and XP23829, a Novel Fumaric Acid Ester (FAE) (P1.201) (2014) (0)
Editorial Board (2011) (0)
Abstract 1543: Discovery of antibodies for ADC therapy from cancer patients who show durable clinical response to checkpoint inhibitors (2019) (0)
The P2Y11 receptor is associated with narcolepsy and with higher susceptibility to ATP induced cell death in T lymphocytes and NK cells. (47.5) (2011) (0)
Peptide determinant affecting immunity (1988) (0)
A phase I study of oral vitamin D3 in boys with X-linked adrenoleukodystrophy (2021) (0)
1023: EXPLORING THE ANTI-INFLAMMATORY EFFECTS OF THE AMYLOIDOGENIC HEXAPEPTIDE, AMYLIN28-33, IN SEPSIS (2015) (0)
Peripheral T Cell Function Opposing Activities in Selection and Modulates Tolerance through mir-181a-1/b-1 (2015) (0)
A phase I study of oral vitamin D3 supplementation in boys with X-linked adrenoleukodystrophy (2022) (0)
Multiple Sclerosis Followed by Neuromyelitis Optica Spectrum Disorder (2022) (0)
Capturing pathogenic immune cells before they home to brain. (2021) (0)
Chapter 3 Local tissue Transglutaminase activity directs experimental Multiple Sclerosis pathology (2010) (0)
Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS (2017) (0)
HLA and T cell receptor associations in narcolepsy, a disorder associated with the selective loss of hypocretin neurons (47.17) (2011) (0)
Sa.12. Blocking Angiotensin II Suppresses IL-12 Signaling in Autoreactive Th Cells and Treats Autoimmune Neuroinflammation (2006) (0)
Roadmap for understanding mechanisms on how Epstein–Barr virus triggers multiple sclerosis and for translating these discoveries in clinical trials (2023) (0)
Relationship Between Infections and Absolute Lymphocyte Count During Phase 3 and Open-label Extension Trials of Ozanimod in Patients With Relapsing Multiple Sclerosis (P7-3.002) (2023) (0)
Proteomic Profiling of Multiple Sclerosis Lesions Identify Potential Targets for Therapy (2007) (0)
Janus Faces of Amyloid Proteins in Neuroinflammation (2014) (0)
Efficacy in Neuroautoimmunity Treatment Requires B Cells for β IFN (2015) (0)
Mobilization of innate and adaptive antitumor immune responses by the RNP-targeting antibody ATRC-101 (2022) (0)
Encephalomyelitis Experimental Autoimmune Proteins Underlies Therapeutic Efficacy in Chaperone Activity of Small Heat Shock Immunology (2013) (0)
Michael Sela: Scientist, statesman, sage (1924–2022) (2022) (0)
Analysis of B Cell Subsets in Multiple Sclerosis Patients on Immunomodulatory Therapy Reveals Modulation of CD19+CD24hiCD38hi Cells with Implications for the Diagnosis and Monitoring of MS (P03.224) (2013) (0)
Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models (2018) (0)
Molecular analysis of TCR repertoire of T cell infiltrate in polymyiositis muscle: Evidence for restricted α/β rearrangement (1991) (0)
[T-cell receptor repertoire in tumor infiltrating lymphocytes within malignant brain tumors]. (1992) (0)
IN EXPERIMENTAL ALLERGIC ENCEPHALOMYELITI S (1990) (0)
Effect of GM 6001 blood-brain barrier permeability and pathology in EAE Blood-brain barrier index * Inflammation + Demyelination § Treatment group Brain Spinal cord Brain Spinal cord Brain + spinal cord (0)
Medical Mystery — Paradoxical Embolism (2007) (0)
An intrinsically disordered protein, osteopontin, driving neuropathology in Alzheimer's dementia. (2023) (0)
Rna profiling in grey and white matter tissue yields clues towards multiple sclerosis etiology (2013) (0)
Vitamin D Status as a Risk Factor for Cerebral Demyelination in X-Linked Adrenoleukdystrophy (S60.005) (2013) (0)
Eary Changes in Experimental Anterior Ischemic Optic Neuropathy and Treatment with -B Crystallin (2009) (0)
Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM (2022) (0)
Therapy of autoimmune diseases with antibodies to immune response gene products (1984) (0)
This information is current as Innate and Adaptive Immune Systems for the Treatment of Autoimmunity via the An Immunomodulatory GpG Oligonucleotide (2003) (0)
Therapeutic Peptides That Block Interaction of T Cells with MHC in Experimental Allergic Encephalomyelitis (1993) (0)
OR.67. Microarray Identified Lipids Modulate Autoimmune Demyelinating Disease (2006) (0)
Chapter 14 Specific Immunotherapeutic Strategies : Lessons from Myelin Basic Protein-Induced Experimental Allergic Encephalomyelitis (0)
067 Neurofilament light chain concentration predicts risk of relapse in participants with relapsing multiple sclerosis in phase 3 ozanimod trials (2021) (0)
The use of the polymerase chain reaction to analyze HLA class II sequence polymorphism and genetic susceptibility to myasthenia gravis (1988) (0)
Therapy of Autoimmune Diseases Using Antibodies to Molecules of the Major Histocompatibility Complex (2020) (0)
List of Contributors (2020) (0)
Methods and immune modulatory nucleic acid preparations for the prevention and treatment of diseases (2003) (0)
Experimental “autoimmune” versus “allergic” encephalomyelitis (1998) (0)
Autoantigen in Multiple Sclerosis Responsible for Its Incorrect Assignment as an B-Crystallin Is α Chaperone Activity of (2011) (0)
Author response: Calibration of cell-intrinsic interleukin-2 response thresholds guides design of a regulatory T cell biased agonist (2021) (0)
Mice Mediates Inflammatory Arthritis in Autoimmunity against Fibrinogen (2009) (0)
OR.58. Lipids as Autoantigens and Therapeutic Immune Modulators in Autoimmune Demyelination (2008) (0)
Disease Outcomes With Ublituximab in Participants With Highly Active Disease: Subpopulation Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis (P6-3.002) (2023) (0)
Protein microarray characterization of the autoantibody response in systemic lupus erythematosus and related diseases (2001) (0)
Erratum to: Parsing Physiological Functions of Erythropoietin One Domain at a Time (2015) (0)
Abstract 3966: Mining the cancer immuno-responsome: The identification of functional antitumor antibodies from patients receiving checkpoint inhibitors (2018) (0)
Limited heterogeneity of rearranged T-cell receptor V α transcripts in brains of multiple sclerosis patients (1991) (0)
Involvement of nitric oxide in CNS demyelination and inflammation (1995) (0)
Reply to Fillmore et al.: Additional evidence of non–SARS-CoV-2 coronavirus cross-immunity (2022) (0)
Compositions for use in a method tilbehandling of a human suffering from sclerosis afdissemineret (1991) (0)
A Phase 1 Study of Oral Vitamin D3 in Boys and Young Men With X-Linked Adrenoleukodystrophy (2023) (0)
An AIDS vaccine in sight (2001) (0)
Autoimmune Encephalomyelitis Nogo-A Modulates Experimental Immunity to the Extracellular Domain of Lawrence (2004) (0)
HLA class II allelic variation and susceptibility to pemphigus vulgaris (major histocompatibility complex/autolmmunlty/polymerase chain reaction/sequence polymorphism/oligonucleotide probes) (2016) (0)
Peptide analogs of human myelin basic protein with substitution at position 91 for the treatment of multiple sclerosis (1995) (0)
Interferon- β exacerbates Th17 inflammatory diseases Relapse-remitting multiple sclerosis (RRMS) Interferon- (2017) (0)
3,4-DAA, an orally active synthetic tryptophan catabolite, treats established autoimmune neuroinflammation (2005) (0)
and Localization to Intracellular Sites through Enhancement of Gene Expression Vaccine for Reversal of Hyperglycemia Improved Efficacy of a Tolerizing DNA (2008) (0)
Mhamad Abou-Hamdan, (2015) (0)
Monocyte-Derived Dendritic Cells Th17 Cells Induce Th1-Polarizing (2013) (0)
PATIENT-REPORTED OUTCOMES AND DISABILITY IN MULTIPLE SCLEROSIS (2015) (0)
Interferon-Beta Alters Monocytes and B-Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. (P1.199) (2014) (0)
The Uptake of [ z3 H ] Aminobutyric Acid in the Goldfish Retina ( Carissius auratus / horizontal cells / amacrine cells / light-stimulated retinas ) (0)
graft-versus-leukemia activity disease protection by Th-2 polarization while sparing Preemptive HMG-CoA reductase inhibition provides graft-versus-host (2013) (0)
A method and immunomodulating nucleic acid compositions for the prevention and treatment of diseases (2003) (0)
Anti-T cell receptor determinants for the treatment of autoimmune diseases (1989) (0)
Erratum to: Parsing Physiological Functions of Erythropoietin One Domain at a Time (2015) (0)
Augmentation of a neuroprotective myeloid state by hematopoietic cell transplantation (2023) (0)
1393: AN AMYLOIDOGENIC HEXAPEPTIDE, AMYLIN, ATTENUATES INFLAMMATION AND ACUTE LUNG INJURY IN MURINE SEPSIS (2016) (0)
Biological Significance of Anti–SARS-CoV-2 Antibodies (2020) (0)
Inflammatory Arthritis in Mice Autoimmunity against Fibrinogen Mediates (2009) (0)
Mice develop B-lymphocyte–dependent delayed cognitive deficits weeks after stroke (2013) (0)
Autoimmunity: 2000 and Beyond, Newport Beach, California, February 11–13, 2000 (2004) (0)
Detection of disease-specific restriction fragment length polymorphisms in pemphigus vulgaris linked to the DQwl and DQw3 alleles of the HLA-D region (HLA-disease associations/autoimmunity) (2016) (0)
Utilisation therapeutique et diagnostique de profils de specificite d'anticorps (2002) (0)
[Pertussis vaccination 1985: an update]. (1985) (0)
T.130. Small Heat Shock Proteins as Novel Therapeutic Treatments for Autoimmune Diseases (2009) (0)
OR.47. Platelet Derived Growth Factor Receptor as a Therapeutic Target for Rheumatoid Arthritis (2008) (0)
Methods and compositions for immunomodulatory nucleic acids preventing and treating diseases. (2003) (0)

This paper list is powered by the following services:

Other Resources About Lawrence Steinman

What Schools Are Affiliated With Lawrence Steinman?

Lawrence Steinman is affiliated with the following schools:

Lawrence Steinman's Academic­Influence.com Rankings

Lawrence Steinman's Degrees

Why Is Lawrence Steinman Influential?

Lawrence Steinman's Published Works

Published Works

Other Resources About Lawrence Steinman

What Schools Are Affiliated With Lawrence Steinman?

Lawrence Steinman's AcademicInfluence.com Rankings